Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer Journal Article
| Authors: | Dalbagni, G.; Herr, H. W. |
| Article Title: | Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer |
| Abstract: | Bacille Calmette-Guerin (BCG) is the most effective therapy for CIS of the bladder. Although several series have shown a decrease in recurrence and progression of T1 tumor, this effect is temporary. More than one half of patients with T1 tumors treated with BCG will progress over the long-term. A second course of BCG is indicated after an initial complete response. There is no definitive answer regarding the efficacy of maintenance therapy or the optimum dose of BCG. Randomized trials are needed to address these issues in a more conclusive manner. Phase III trials have shown that mitomycin C can be as effective as BCG in the management of papillary tumors; however, BCG is more effective in patients with CIS and high-risk superficial tumors. |
| Keywords: | clinical trial; review; cancer recurrence; cancer growth; drug efficacy; antineoplastic agents; treatment indication; bcg vaccine; neoplasm recurrence, local; drug administration schedule; tumor markers, biological; bladder cancer; urinary bladder neoplasms; cancer vaccines; disease progression; carcinoma in situ; long term care; remission induction; mitomycin c; phase 3 clinical trial; administration, intravesical; dose calculation; humans; human; priority journal |
| Journal Title: | Urologic Clinics of North America |
| Volume: | 27 |
| Issue: | 1 |
| ISSN: | 0094-0143 |
| Publisher: | W.B. Saunders Co-Elsevier Inc. |
| Date Published: | 2000-02-01 |
| Start Page: | 137 |
| End Page: | 146 |
| Language: | English |
| PUBMED: | 10696252 |
| PROVIDER: | scopus |
| DOI: | 10.1016/S0094-0143(05)70241-X |
| DOI/URL: | |
| Notes: | Export Date: 18 November 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work